Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer

被引:30
作者
Zhao, Xiaoyan [1 ]
Cai, Li [1 ]
Hu, Yu [1 ]
Wang, Huafang [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Hematol, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
immunotherapy; natural killer cells; umbilical cord blood; cancer; cytotoxicity; CHIMERIC ANTIGEN RECEPTOR; TGF-BETA RECEPTOR; NK CELLS; T-CELLS; NK-92; CELLS; TRANSPLANTATION; SAFETY; GENERATION; DONOR;
D O I
10.3389/fimmu.2020.584099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells are a predominant part of innate immune cells and play a crucial role in anti-cancer immunity. NK cells can kill target cells nonspecifically, and their recognition of target cells is not restricted by the major histocompatibility complex. NK cells also fight against tumor cells independently of antibodies and prior activation. Of note, umbilical cord blood (UCB) is a rich source of NK cells. Immunotherapies based on UCB-derived NK cells are becoming increasingly researched, and the investigations are producing encouraging results. In recent years, non-modified and modified UCB-derived NK cells have been successfully developed to fight against tumor cells. Herein, UCB-derived NK cell-based immunotherapy is a potential strategy for the treatment of cancer in the future. In this review, we focus on discussing the biological characteristics of UCB-derived NK cells and their application prospects in anti-tumor immunotherapy, including the latest preclinical and clinical researches.
引用
收藏
页数:8
相关论文
共 68 条
[1]   Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].
Andre, Pascale ;
Denis, Caroline ;
Soulas, Caroline ;
Bourbon-Caillet, Clarisse ;
Lopez, Julie ;
Arnoux, Thomas ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Gauthier, Laurent ;
Morel, Ariane ;
Rossi, Benjamin ;
Remark, Romain ;
Breso, Violette ;
Bonnet, Elodie ;
Habif, Guillaume ;
Guia, Sophie ;
Lalanne, Ana Ines ;
Hoffmann, Caroline ;
Lantz, Olivier ;
Fayette, Jerome ;
Boyer-Chammard, Agnes ;
Zerbib, Robert ;
Dodion, Pierre ;
Ghadially, Hormas ;
Jure-Kunkel, Maria ;
Morel, Yannis ;
Herbst, Ronald ;
Narni-Mancinelli, Emilie ;
Cohen, Roger B. ;
Vivier, Eric .
CELL, 2018, 175 (07) :1731-+
[2]   Umbilical cord blood transplantation: the first 25 years and beyond [J].
Ballen, Karen K. ;
Gluckman, Eliane ;
Broxmeyer, Hal E. .
BLOOD, 2013, 122 (04) :491-498
[3]   Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches [J].
Bottino, Cristina ;
Dondero, Alessandra ;
Bellora, Francesca ;
Morette, Lorenzo ;
Locatelli, Franco ;
Pistoia, Vito ;
Moretta, Alessandro ;
Castriconi, Roberta .
FRONTIERS IN IMMUNOLOGY, 2014, 5
[4]   Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma [J].
Burga, Rachel A. ;
Yvon, Eric ;
Chorvinsky, Elizabeth ;
Fernandes, Rohan ;
Cruz, C. Russell Y. ;
Bollard, Catherine M. .
CLINICAL CANCER RESEARCH, 2019, 25 (14) :4400-4412
[5]   Manufacturing Natural Killer Cells as Medicinal Products [J].
Chabannon, Christian ;
Mfarrej, Bechara ;
Guia, Sophie ;
Ugolini, Sophie ;
Devillier, Raynier ;
Blaise, Didier ;
Vivier, Eric ;
Calmels, Boris .
FRONTIERS IN IMMUNOLOGY, 2016, 7
[6]   A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells [J].
Chang, Yu-Hsiang ;
Connolly, John ;
Shimasaki, Noriko ;
Mimura, Kousaku ;
Kono, Koji ;
Campana, Dario .
CANCER RESEARCH, 2013, 73 (06) :1777-1786
[7]   Natural killer cells and other innate lymphoid cells in cancer [J].
Chiossone, Laura ;
Dumas, Pierre-Yves ;
Vienne, Margaux ;
Vivier, Eric .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (11) :671-688
[8]   Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice [J].
Chu, Yaya ;
Hochberg, Jessica ;
Yahr, Ashlin ;
Ayello, Janet ;
van de Ven, Carmella ;
Barth, Matthew ;
Czuczman, Myron ;
Cairo, Mitchell S. .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) :333-344
[9]   B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma [J].
Cohen, Adam D. ;
Garfall, Alfred L. ;
Stadtmauer, Edward A. ;
Melenhorst, J. Joseph ;
Lacey, Simon F. ;
Lancaster, Eric ;
Vogl, Dan T. ;
Weiss, Brendan M. ;
Dengel, Karen ;
Nelson, Annemarie ;
Plesa, Gabriela ;
Chen, Fang ;
Davis, Megan M. ;
Hwang, Wei-Ting ;
Young, Regina M. ;
Brogdon, Jennifer L. ;
Isaacs, Randi ;
Pruteanu-Malinici, Iulian ;
Siegel, Don L. ;
Levine, Bruce L. ;
June, Carl H. ;
Milone, Michael C. .
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) :2210-2221
[10]   Characterization of cord blood natural killer cells:: Implications for transplantation and neonatal infections [J].
Dalle, JH ;
Menezes, J ;
Wagner, É ;
Blagdon, M ;
Champagne, J ;
Champagne, MA ;
Duval, M .
PEDIATRIC RESEARCH, 2005, 57 (05) :649-655